Tuberc Respir Dis > Volume 83(Supple 1); 2020 > Article |
|
Authors’ Contributions
Conceptualization: Ungcharoen U, Sriplung H, Mahasirimongkol S, Chongsuvivatwong V. Methodology: Ungcharoen U, Sriplung H, Mahasirimongkol S, Mokmued P, Chongsuvivatwong V. Formal analysis: Ungcharoen U, Sriplung H. Data curation: Ungcharoen U, Chusri S. Software: Ungcharoen U, Chongsuvivatwong V. Validation: Wichukchinda N, Mahasirimongkol S. Investigation: Chusri S, Chongsuvivatwong V. Writing - original draft preparation: Ungcharoen U, Sriplung H. Writing - review and editing: Ungcharoen U, Sriplung H, Wichukchinda N, Wattanapokayakit S, Mokmued P. Approval of final manuscript: all authors.
Characteristic | New pulmonary TB patients (n=30) | Fast (n=4) | Intermediate (n=14) | Slow (n=12) | p-value |
---|---|---|---|---|---|
Age, yr | 44±14 | 57±8.4 | 40.7±14.2 | 43.5±13.5 | 0.120* |
Weight, kg | 53.9±7.9 | 53.7±3.0 | 57.5±8.0 | 50.8±7.8 | 0.100* |
BMI, kg/m2 | 20.4±3.1 | 21.6±2.8 | 19.5±3 | 21±3.2 | 0.310* |
Sex | >0.999† | ||||
Male | 17 (56.7) | 2 (50) | 8 (57.1) | 7 (58.3) | |
Female | 13 (43.3) | 2 (50) | 6 (42.9) | 5 (41.7) | |
History of TB contact | 0.838† | ||||
Yes | 6 (20) | 0 (0) | 3 (21.4) | 3 (25) | |
No | 24 (80) | 4 (100) | 11 (78.6) | 9 (75) | |
Occupation | 0.986† | ||||
Farmer/worker/merchant | 12 (40) | 2 (50) | 6 (42.9) | 4 (33.3) | |
Government officer | 11 (36.7) | 1 (25) | 5 (35.7) | 5 (41.7) | |
Student | 2 (6.7) | 0 (0) | 1 (7.1) | 1 (8.3) | |
Healthcare workers | 2 (6.7) | 0 (0) | 1 (7.1) | 1 (8.3) | |
Unemployed | 3 (10) | 1 (25) | 1 (7.1) | 1 (8.3) | |
Former smoking | 0.338† | ||||
Yes | 3 (10) | 0 (0) | 3 (21.4) | 0 (0) | |
No | 27 (90) | 4 (100) | 11 (78.6) | 12 (100) | |
Comorbidities | |||||
Diabetes mellitus | 0.180† | ||||
Yes | 5 (16.7) | 2 (50) | 2 (14.3) | 1 (8.3) | |
No | 25 (83.3) | 2 (50) | 12 (85.7) | 11 (91.7) | |
Hypertension | 0.134† | ||||
Yes | 5 (16.7) | 2 (50) | 1 (7.1) | 2 (16.7) | |
No | 25 (83.3) | 2 (50) | 13 (92.9) | 10 (83.3) | |
Dyslipidemia | 0.056† | ||||
Yes | 4 (13.3) | 2 (50) | 2 (14.3) | 0 (0) | |
No | 26 (86.7) | 2 (50) | 12 (85.7) | 12 (100) | |
Liver function tests prior treatment§ | |||||
Albumin, g/dL | 3.9±0.4 | 3.8±0.4 | 3.9±0.4 | 3.8±0.5 | 0.731* |
AST, U/L | 18.0 (16-21.5) | 20.5 (12.8-29.2) | 19.5 (18-22) | 16.5 (15.5-18.2) | 0.188‡ |
ALT, U/L | 12.5 (9-20.8) | 13 (8-21.5) | 11.5 (8.2-19.8) | 15 (11.8-21) | 0.330‡ |
ALP, U/L | 86 (73.3-102.5) | 82 (73.5-84.8) | 80 (70.8-96.8) | 91 (80-105.5) | 0.397‡ |
Total bilirubin, g/dL | 0.5±0.3 | 0.5±0.4 | 0.6±0.3 | 0.4±0.3 | 0.266* |
Direct bilirubin, g/dL | 0.2 (0.1-0.3) | 0.2 (0.1-0.2) | 0.2 (0.1-0.3) | 0.1 (0.1-0.2) | 0.827‡ |
Dose of anti-TB drugs, mg/kg/day | |||||
Isoniazid | 5.5±0.8 | 5.6±0.3 | 5.7±0.8 | 5.3±0.7 | 0.424* |
Rifampicin | 10±1.2 | 9.8±1.2 | 10.2±0.8 | 9.9±1.5 | 0.807* |
Ethambutol | 17.8±1.7 | 15.8±1.3 | 18.1±1.5 | 18.1±1.9 | 0.051* |
Pyrazinamide | 23.5±3.2 | 22±3.3 | 23.6±3.3 | 24±3.1 | 0.586* |
Characteristic | Univariate analysis coefficient (β) |
Multivariate analysis |
|||
---|---|---|---|---|---|
Coefficient (β) | Standard error | 95% CI | p-value | ||
Intercept | - | 2.71 | 1.07 | 0.63 to 4.80 | 0.018* |
Weight ≥50 kg | -1.36 | -1.48 | 0.63 | -2.71 to -0.25 | 0.027* |
Diabetes mellitus (yes) | -1.60 | 0.45 | 1.81 | -3.1 to 4.0 | 0.805 |
Dyslipidemia (yes)† | -2.01 | -0.25 | 1.73 | -3.65 to 3.14 | 0.884 |
Hypertension (yes) | -1.49 | -1.06 | 1.14 | -3.27 to 1.17 | 0.360 |
NAT2 acetylators (reference=fast) | |||||
Intermediate | 2.53 | 1.41 | 0.94 | -0.45 to 3.26 | 0.150 |
Slow | 3.68 | 3.14 | 0.94 | 1.3 to 5.0 | 0.003* |
Study | Regions of Thailand |
Percentage of NAT2 acetylator |
Thai population | NAT2 genotyping method | ||
---|---|---|---|---|---|---|
Fast | Intermediate | Slow | ||||
Kukongviriyapan et al. (2003) [19] | Northeastern | 63.8 | - | 36.2 | Healthy | Polymerase chain reaction with restriction fragment length polymorphism assays |
Wattanapokayakit et al. (2016) [17] | Northern and central | 15.3 | 62.4 | 22.4 | TB patients (non-hepatotoxic controls) | NAT2 haplotyping from four common SNPs |
Ungcharoen et al. (2020) (present study) | Southern | 10.9 | 36.4 | 52.7 | New TB patients | Haplotype-specific PCR for NAT2 diplotyping |
Usanee Ungcharoen
https://orcid.org/0000-0003-1665-0684
Hutcha Sriplung
https://orcid.org/0000-0002-8483-0460
A Study on Chronic Far Advanced Pulmonary Tuberculosis Patients1987 March;34(1)
Result of Negative Conversion for Pulmonary Tuberculosis Patients at Sanatorium1986 December;33(4)